



04-22-02

GP1632 #8

Practitioner's Docket No. MWH-008US

PATENT

## IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

RECEIVED

In re application of: Denton, R. Rex, et al.  
Application No.: 09/889,866  
I.A. Filing Date: August 11, 2000  
I.A. No.: PCT/US00/22175

Art Unit: 1632  
Examiner: D. Crouch

APR 24 2002

TECH CENTER 1600/2900

For: Drug Target Isogenes: Polymorphisms in the Immunoglobulin E Receptor Beta  
Chain Gene

RECEIVED

Assistant Commissioner for Patents  
Washington, D.C. 20231

MAY 08 2002

TECH CENTER 1600/2900

TRANSMITTAL OF SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT  
WITHIN THREE MONTHS OF FILING OR  
BEFORE MAILING OF FIRST OFFICE ACTION (37 C.F.R. section 1.97(b))

Enclosed herewith please find:

1. Identification of Time of Filing the Accompanying Information Disclosure Statement
2. Information Disclosure Statement by Applicant Form PTO/SB/08A (1 page)
3. Information Disclosure Statement by Applicant Form PTO/SB/08B (3 pages)
4. Copies of Listed References Accompanying this Statement (24-Total)

Date: 18 - April - 2002  
Tel. No. 203-786-3468  
Registration No. 47,934  
Customer No. 25106

Sandra L. Shaner  
Sandra L. Shaner  
Genaissance Pharmaceuticals, Inc.  
Five Science Park  
New Haven, CT 06511

## CERTIFICATION UNDER 37 C.F.R. SECTION 1.10\*

(Express Mail label number is *mandatory*.)(Express Mail certification is *optional*.)

I hereby certify that this correspondence and the documents referred to as attached therein are being deposited with the United States Postal Service on April 18, 2002 (date), in an envelope as "EXPRESS MAIL POST OFFICE TO ADDRESSEE" service under 37 C.F.R. Section 1.10, Mailing Label Number EL 59 A 594 953 US addressed to Box PCT, Assistant Commissioner for Patents, Washington, D.C. 20231.

Cathy Wilcox

(type or print name of person mailing paper)

Cathy Wilcox  
Signature of person mailing



RECEIVED

MAY 0 8 2002

TECH CENTER 1600/2900

RECEIVED

APR 24 2002

TECH CENTER 1600/2900  
PATENT

Practitioner's Docket No. MWH-008US

**IN THE UNITED STATES PATENT AND TRADEMARK OFFICE**

In re application of: Denton, R. Rex, et al.  
Application No.: 09/889,866  
I.A. Filing Date: August 11, 2000  
I.A. No.: PCT/US00/22175

Art Unit: 1632  
Examiner: D. Crouch

For: Drug Target Isogenes: Polymorphisms in the Immunoglobulin E Receptor Beta Chain Gene

Assistant Commissioner for Patents  
Washington, D.C. 20231

**IDENTIFICATION OF TIME OF FILING THE ACCOMPANYING  
INFORMATION DISCLOSURE STATEMENT**

The information disclosure statement submitted herewith is being filed within three months of the filing date of the application or date of entry into the national stage of an international application or before the mailing date of a first Office action on the merits, whichever event occurs last. 37 C.F.R. section 1.97(b).

Date: 18 - April - 2002  
Tel. No. 203-786-3468  
Registration No. 47,934  
Customer No. 25106

Sandra L. Shaner  
Sandra L. Shaner  
Genaissance Pharmaceuticals, Inc.  
Five Science Park  
New Haven, CT 06511

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

**Complete if Known**

<b>Application Number</b>	09/889,866
<b>Filing Date</b>	08/11/2000
<b>First Named Inventor</b>	R. Rex Denton
Group Art Unit	1632
<b>Examiner Name</b>	D. Crouch
<b>Attorney Docket Number</b>	MWH-0081US

(use as many sheets as necessary)

Sheet 1 of 1

Attorney Docket Number | MWH-008US

APR 24 2002

APR 18 2002

PATENT & TRADEMARK OFFICE

## U.S. PATENT DOCUMENTS

**TECH CENTER 1600/2900**

[illegible]

**FOREIGN PATENT DOCUMENTS**

[illegible]

Examiner  
Signature

Date	
Considered	

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup> Unique citation designation number. <sup>2</sup> See attached Kinds of U.S. Patent Documents. <sup>3</sup> Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). <sup>4</sup> For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. <sup>5</sup> Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. <sup>6</sup> Applicant is to place a check mark here if English language Translation is attached.

**Burden Hour Statement:** This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, Patent and Trademark Office, Washington, DC 20231. **DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO:** Assistant Commissioner for Patents, Washington, DC 20231.

+

Please type a plus sign (+) inside this ☐

PTO/SB/08B (10-96)  
Approved for use through 10/31/99. OMB 0651-0031  
Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE  
Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449B/PTO

# **INFORMATION DISCLOSURE STATEMENT BY APPLICANT**

(use as many sheets as necessary)

Sheet 1 of 3

## **Complete if Known**

Application Number	09/889,866	<b>RECEIVED</b> APR 24 2002 TECH CENTER 1600/2900
Filing Date	08/11/2000	
First Named Inventor	R. Rex Denton	
Group Art Unit	1632	
Examiner Name	D. Crouch	
Attorney Docket Number	MWH-008US	

## **OTHER PRIOR ART -- NON PATENT LITERATURE DOCUMENTS**

Examiner Initials*	Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.
	DA	BACANU S-A, DEVLIN B & ROEDER K, "The Power of Genomic Control," Am. J. Hum Genet, Vol. 66, p. 1933-44, ( May 11, 2000).
	DB	BAILEY DS, BONDAR A & FURNESS LM, "Pharmacogenomics-It's not just pharmacogenetics," Curr Opin in Biotech, Vol 9, p. 595-601, (1998).
	DC	BERTILSSON L, DAHL M-L, TYBRING G, "Pharmacogenetics of antidepressants: clinical aspects," Acta Psychiatr Scand, Vol 96 (Suppl 391), p. 14-21, (1997).
	DD	CHAKRAVARTI A, "Population genetics-making sense out of sequence," Nature genetics, Vol 21, p. 56-60, ( January 1999).
	DE	CHAKRAVARTI A, "It's raining SNPS, hallelujah?," Nature genetics, Vol. 19, p. 216-7, (July 1998).
	DF	CLARK AG et al., "Haplotype Structure and Population Genetic Inferences from Nucleotide-Sequence Variation in Human Lipoprotein Lipase," Am J Hum Genet, Vol 63, p. 595-612, ( July 29, 1998).
	DG	COHEN J, "Medicine: Developing prescriptions with a personal touch," Science, Vol 275, p. 776, ( February 7, 1997).
	DH	HILL AVS et al., "Human genetic variation and its impact on public health and medicine," Health and Disease, Oxford University Press (New York), p. 62-74, (1999).
	DI	JUDSON R, STEPHENS JC & WINDEMUTH A, "The predictive power of haplotypes in clinical response," Pharmacogenomics, Vol. 1 ( No. 1), p. 1-12, ( 2000).
	DJ	KALOW W, OZDEMIR V, TANG B-K, TOTHFALUSI L & ENDRENYI L, "The Science of pharmacological variability: An essay," Clin Pharmacol Ther, Vol. 66, p. 445-7, (November 1999).
	DK	KLEYN PW & VESELL ES, "Pharmacogenomics: Genetic Variation as a Guide to Drug Development," Science, Vol 281, p. 1820-1, ( September 18, 1998).


Examiner  
Signature

Date  
Considered

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup> Unique citation designation number. <sup>2</sup> Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.

Please type a plus sign (+) inside this 

APR 18 2002

PTO/SB/08B (10-96)

Approved for use through 10/31/99. OMB 0651-0031

Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449B/PTO

# **INFORMATION DISCLOSURE STATEMENT BY APPLICANT**

(use as many sheets as necessary)

Sheet 2 of 3

**Complete if Known**

Application Number 09/889,866  
Filing Date 08/11/2000  
First Named Inventor R. Rex Denton  
Group Art Unit 1632  
Examiner Name D. Crouch  
Attorney Docket Number MWH-008US

**RECEIVED**

APR 24 2002

TECH CENTER 1600/2900

## **OTHER PRIOR ART - NON PATENT LITERATURE DOCUMENTS**

Examiner Initials <sup>1</sup>	Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.
	DL	KOLA I, "Complex traits, genes, polymorphisms and the drug discovery/development process," Curr Opin in Biotech, Vol 10., p. 589-92, (1999).
	DM	KWOK P-Y & GU Z, "Single Nucleotide polymorphism libraries: why and how are we building them?," Mol Med Today, Vol. 5, p. 538-43, ( December 1999).
	DN	LU AYH, "Drug-Metabolism research challenges in the new millennium: Individual variability in drug therapy and drug safety," Drug Metab & Disposition, Vol. 26 ( No. 12), p. 1217-1222, (1998).
	DO	MARSHALL A, "Getting the right drug into the right patient," Nature Biotechnology, Vol 15, p. 1249-52, ( November 1997).
	DP	MARSHALL E, "Drug Firms to create public database of genetic mutations," Science, Vol 284, p. 406-7, ( April 16, 1999).
	DQ	-MEYER UA, "Medically relevant genetic variation of drug effects," Health and Disease, Oxford University Press (New York), p. 41-49, (1999).
	DR	PRITCHARD JK, STEPHENS M, ROSENBERG NA & DONNELLY P, "Association mapping in structured populations," Am J Hum Genet, Vol. 67, p. 170-181, (May 26, 2000).
	DS	ROSES AD, "Pharmacogenetics and the practice of medicine," Nature, Vol. 405, p. 857-65, ( June 15, 2000).
	DT	STEPHENS JC, "Single-nucleotide polymorphisms , haplotypes, and their relevance to pharmacogenetics," Mol Diagnosis, Vol. 4 ( No. 4), p. 309-317, (1999).
	DU	ULBRECHT M, HERGETH MT, WIST M, HEINRICH J, BICKEBOLLER H, WICHMANN H-E & WEISS EH, "Association of beta-2-adrenoreceptor variants with bronchial hyperresponsiveness," Am J Respir Crit Care Med, Vol. 161, p. 469-474, (2000).
	DV	WANG DG ET AL., "Large-scale identification, mapping, and genotyping of single-nucleotide polymorphisms in the human genome," Science, Vol. 280, p. 1077-82, (May 15, 1998).

Examiner Signature

Date Considered

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup> Unique citation designation number. <sup>2</sup> Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.

**RECEIVED**

MAY 08 2002

TECH CENTER 1600/2900

+

Approved for use through 10/31/99. OMB 0651-0031

Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

**Complete if Known**

## INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(use as many sheets as necessary)

Sheet

3

of 3

Application Number

09/889.866

Filing Date

08/11/2000
------------

**First Named Inventor**

R. Rex Denton

Group Art Unit

1632

Examiner Name

D. Crouch

Attorney Docket Number

MWH-008US

OTHER PRIOR ART -- NON PATENT LITERATURE DOCUMENTS

Examiner  
Initials\*

Cite  
No.<sup>1</sup>

Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.

DW

WOLF CR, SMITH G & SMITH RL, "Science, medicine, and the future: Pharmacogenetics," Br Med J, Vol. 320, p. 987-90, ( April 8, 2000).

Examiner  
Signature

Date \_\_\_\_\_

Considered

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup> Unique citation designation number. <sup>2</sup> Applicant is to place a check mark here if English language Translation is attached.

**Burden Hour Statement:** This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, Patent and Trademark Office, Washington, DC 20231. **DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO:** Assistant Commissioner for Patents, Washington, DC 20231.

RECEIVED

MAY 08 2002